Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Rhea-AI Summary

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) announced that CEO Fabian Tenenbaum will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021. The presentation will be available on-demand starting January 11 on the Company’s website. Bellerophon focuses on developing therapies for cardiopulmonary and infectious diseases, particularly through its proprietary INOpulse® nitric oxide delivery system.

WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.

The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Company’s website at www.bellerophon.com.

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse^® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

Contacts
At W2O Group:		At LifeSci Advisors:
Julie Normart		Brian Ritchie
(559) 974-3245		(212) 915-2578
jnormart@w2ogroup.com		britchie@lifesciadvisors.com

 

FAQ

When is the H.C. Wainwright Virtual BioConnect 2021 Conference for BLPH?

The conference will take place from January 11-14, 2021.

Who will present at the H.C. Wainwright Conference for BLPH?

Fabian Tenenbaum, the CEO of Bellerophon Therapeutics, will present.

Where can I watch BLPH's presentation from the conference?

The presentation will be available on-demand on the Company's website starting January 11, 2021.

What is the focus of Bellerophon Therapeutics?

Bellerophon Therapeutics focuses on developing therapies for cardiopulmonary and infectious diseases.

What is the INOpulse® program related to BLPH?

The INOpulse® program is a proprietary pulsatile nitric oxide delivery system under development by Bellerophon.